OTHER INFORMATION.
−Removed: the six months ended June 30, 2024, none of the Company’s directors or officers adopted or terminated any contract, instruction
+Added: the nine months ended September 30, 2024, none of the Company’s directors or officers adopted or terminated any contract, instruction
or written plan for the purchase or sale of the Company’s securities that was intended to satisfy the affirmative defense conditions
6 unchanged sentences
BIOPHARMA HOLDINGS, INC.
−Removed: August 14, 2024
+Added: November 13, 2024
Executive Officer (Principal Executive Officer)
−Removed: August 14, 2024
+Added: November 13, 2024
Financial Officer
6 unchanged sentences
(incorporated herein by reference to the Company’s Current Report on Form 8-K filed with the SEC on November 5, 2015).
+Added: Certificate of Amendment, dated August 30, 2024 to Certificate of Incorporation.
+Added: (incorporated herein by reference to the Company’s Current Report on Form 8-K filed with the SEC on September 3, 2024).
Common Stock Purchase Warrant, dated April 5, 2024 (incorporated herein by reference to the Company’s Current Report on Form 8-K filed with the SEC on April 5, 2024).
16 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.